n.a. (CADX)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Market Cap 1.25B
Div & Yield N.A. (N.A)
Cadence Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Cadence Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Cadence Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript

7 Stocks Under $10 With Relative Strength

7 Stocks Under $10 With Relative Strength

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

8 Stocks Under $10 to Avoid at All Costs

8 Stocks Under $10 to Avoid at All Costs

These stocks are not necessarily on their way to bankruptcy, but they do not exhibit the qualities that are precursors to improving fundamental performance.

Pacira: Exparel Approval Easy, Selling Painkiller Harder Challenge

Pacira: Exparel Approval Easy, Selling Painkiller Harder Challenge

Pacira must convince hospitals that its long-acting painkiller benefits patients and saves them money.

5 Stocks Showing Relative Strength in a Weak Market

5 Stocks Showing Relative Strength in a Weak Market

If the short-sellers can't knock these names down today, then there could be an underlying bid on these stocks that makes them attractive buys.

Biotech Stock Mailbag: Cadence Pharma

Biotech Stock Mailbag: Cadence Pharma

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

Biotech Sector Weekly Rewind

Biotech Sector Weekly Rewind

Adam Feuerstein's take on the biotech sector's hits and misses during the week ended Nov. 5, 2010.

Cadence CEO Discusses Q3 2010 Results - Earnings Call Transcript

Cadence CEO Discusses Q3 2010 Results - Earnings Call Transcript

Cadence CEO Discusses Q3 2010 Results - Earnings Call Transcript

Cadence: When A Drug Approval Sinks Stock

Cadence's pain drug was approved, but the stock sank because investors are more concerned about a financing overhang and the drug's commercial launch.

FDA Ends October With Drug Approvals, Rejection

FDA approves drugs from Forest Labs and Avanir but rejects Biodel in what was a tough month overall for drug reviews.

Biotech Calendar: Key Dates for November

Here's a list of November's potentially stock-moving biotech events

Biotech Stock Mailbag: Exact Sciences

Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.

21 Drugs Facing FDA Approval Decisions

21 Drugs Facing FDA Approval Decisions

Here is the updated list of drugs facing FDA approval decisions.

Cadence Pharmaceuticals Inc. Q2 2010 Earnings Call Transcript

Cadence Pharmaceuticals Inc. Q2 2010 Earnings Call Transcript

Cadence Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript

Cadence Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript

Questioning MannKind's FDA Delay: BioBuzz

Mannkind needs to clarify the cause and extent of the FDA's decision to delay approval of its inhaled insulin device.

FDA Delays Cadence Drug Review: BioBuzz

FDA Delays Cadence Drug Review: BioBuzz

IV Acetaminophen review pushed back to February 2010.

FDA Extends Review Of Cadence's IV Drug Acetavance

FDA Extends Review Of Cadence's IV Drug Acetavance

Cadence Pharma says FDA expects to make a decision on its IV painkiler by mid-February

Biotech Calendar: Key FDA Action Dates

Biotech Calendar: Key FDA Action Dates

A quick and dirty guide to upcoming FDA approval dates for biotech drugs.

Cadence Pharma Seeks Approval Of IV Fever Drug

Cadence Pharma Seeks Approval Of IV Fever Drug

Cadence requests FDA approval of Acetavance, an IV form of acetaminophen for pain and fever

Dendreon's $230M Haul Says It All

Dendreon's $230M Haul Says It All

Dendreon raised $230 million in the year's second-largest biotech follow-on stock offering.

Cadence 4Q Loss Narrows Slightly On Lower Costs

Cadence Pharmaceuticals' 4th-quarter loss narrows slightly on lower expenses

Health Winners & Losers: ImClone

Health Winners & Losers: ImClone

ImClone soars on a buyout bid.

Friday's Health Winners & Losers

Cadence suffers when its drug for pain doesn't work as planned.

Cadence Shares Hurt by Pain Drug Trial

The drug Acetavance fell short in a late-stage trial.

Thursday's Health Winners & Losers

Thursday's Health Winners & Losers

Hollis-Eden is up.

Cadence Pharma Loss Widens

Expenses grew at the newly public company.